Sage Journals: Discover world-class research

Abstract

Objective:

Antidepressants, in particular Atomextine, along with stimulants have demonstrated benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. As ADHD has been associated with sleep disorders, it is assumed that Agomelatiine might serve as a therapeutic alternative to treat patients with the ADHD refractory to first line medications.

Method:

Ten late adolescents were evaluated in a placebo controlled manner.

Results:

Agomelatine’s effect was superior to that of placebo but appeared to be less than that of first line medications such as methylphenidate.

Conclusion:

Agomelatine may be a useful second line medication for individuals with ADHD, particularly if they suffer from additional sleep disorders.

Keywords

psychopharmacology attention deficit disorder neurobiology agomelatine

Get full access to this article

View all access options for this article.

References

American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., revised). Washington, DC: Author.

Biederman

Newcorn

Sprich

(1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry, 148, 564-577.

Faraone

S. V.

Biederman

Keenan

Tsuang

M. T.

(1991). Separation of DSM-III attention deficit disorder and conduct disorder: Evidence from a family-genetic study of American child psychiatric patients. Psychological Medicine, 21, 109-121.

Firestone

(1982). Factors associated with patients’ adherence to stimulant medication. American Journal of Orthopsychiatry, 52, 447-457.

Gualtieri

C. T.

Golden

R. N.

Fahs

J. J.

(1983). New developments in pediatric psychopharmacology. Journal of Developmental & Behavioral Pediatrics, 4, 202-209.

Hunt

R. D.

(1987). Treatment effects of oral and transdermal clonidine in relation to methylphenidate: An open pilot study in ADD-H. Psychopharmacol Bulletin, 123, 111-114.

Hunt

R. D.

(1988). Attention deficit disorder: Diagnosis, assessment and treatment. In Kestenbaum

Williams

(Eds.), Handbook of clinical assessment of patients and adolescents: A biopsychosocial approach (Vol. II, pp. 519-561). New York, NY: New York University Press.

Hunt

R. D.

Minderaa

R. B.

Cohen

D. J.

(1985). Clonidine benefits patients with attention deficit disorder and hyperactivity: Report of a double-blind placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 24, 617-629.

Quintana

Butterbaugh

G. J.

Purnell

L. A. K.

(2007). Fluoexitine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. Child Psychiatry & Human Development, 37, 241-253.

10.

Rapport

M. D.

Denney

DuPaul

G. J.

Gardner

M. J.

(1994). Attention deficit disorder and methylphenidate: Normalization rates, clinical effectiveness, and response prediction in 76 patients. Journal of American Academy of Child Adolescent & Psychiatry, 33, 882-893.

11.

Ward

M. F.

Wender

P. H.

Reimherr

F. W.

(1993). The Wender Utah Rating Scale: An aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. American Journal of Psychiatry, 150, 885-890.

Agomelatine Treatment with Adolescents with ADHD

Abstract

Objective:

Method:

Results:

Conclusion:

Keywords

Get full access to this article

References